BioNTech SE (Nasdaq: BNTX, “BioNTech”) and Kite, a Gilead Company (Nasdaq: GILD, “Kite”) today announced the two companies have entered into a purchase agreement for BioNTech to acquire Kite’s solid tumor neoantigen T cell receptor (TCR) R&D platform and clinical manufacturing facility in Gaithersburg, MD. The acquired Gaithersburg facility will provide production capacity to support clinical trials in the United States and will complement BioNTech’s existing cell therapy manufacturing facility in Idar-Oberstein, Germany. The facility will support the development of BioNTech’s expanding pipeline of novel cell therapies, including cancer product candidates based on its CAR-T Cell amplifying mRNA vaccine (CARVac) and NEOSTIM platforms as well as the newly acquired individualized neoantigen TCR program.
Penn cell therapy pioneer Dr. Carl June wins $1M prize Cell therapy pioneer Dr. Carl June was named the recipient of this year’s $1 million Sanford Lorraine Cross Award for his groundbreaking [….]
Arcellx Closes $115 Million Series C Financing to Advance its Pipeline of Adaptive and Controllable Cell Therapies
Arcellx, a privately held clinical- stage biopharmaceutical company, today announced that it raised $115 million in a Series C financing to advance its pipeline of adaptive and controllable cell therapies. The proceeds will support the company’s development of CART-ddBCMA, a BCMA-specific CAR-modified T-cell therapy currently in Phase 1 and anticipated to begin a pivotal trial in 2022. In addition, the funding will support initiation of clinical trials evaluating ACLX-001 and ACLX-002, cell therapies derived from Arcellx’s uniquely controllable ARC-SparX platform, in multiple myeloma (MM) and acute myelogenous leukemia (AML), respectively.
As some are now calling it, the greater Philadelphia region, or ‘Cellecon Valley, is garnering a lot of attention these days as a rapidly emerging Biopharma cluster, earning a defining spot among the top 10 clusters in the US.
Murat Kalayoglu, MD, PhD, President & CEO, Cartesian Therapeutics, Discusses New Frontline Therapy Treatment for Multiple Myeloma
Murat Kalayoglu, MD, PhD, President & CEO, Cartesian Therapeutics, Discusses New Frontline Therapy Treatment for Multiple Myeloma Cartesian Therapeutics, a biopharmaceutical company that specializes in mRNA-engineered cell therapy, recently announced [….]
At BioBuzz, we’ve written extensively about the promise of cell and gene therapeutics for both patients and the companies developing these revolutionary personalized medicines.
Cartesian Therapeutics Initiates Phase 2 Clinical Trial of First RNA-Engineered Cell Therapy for Frontline Cancer
Cartesian Therapeutics Initiates Phase 2 Clinical Trial of First RNA-Engineered Cell Therapy for Frontline Cancer Descartes-11 specifically designed to integrate into standard treatment regimen for newly diagnosed multiple myeloma without [….]
Neil Sheppard is an Immunologist educated in the UK at the Universities of Bristol and Oxford. He has over 18 years’ experience in the fields of vaccines and immunotherapies, including over a dozen years leading drug discovery and development programs in Big Pharma and Biotech.